Molecular Templates to present preclinical data of ETB platform technology at 5th RNAi and miRNA World Congress

Apr 22 2011

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of small biologic therapies called Engineered Toxin Bodies (ETB), announced today that it will present preclinical data in a poster presentation at the 5^th Annual RNAi and miRNA World Congress in Boston, MA during April 26-27, 2011. In a presentation, entitled "Engineered Toxin Bodies (ETB) Deliver siRNA Payloads to the Cytosol of Targeted Cells," the company will report the development of ETBs that are capable of delivering siRNA molecules in a target and cell specific manner. ETBs possess biological active properties that allow them to target and internalize against specific extracellular receptors and then mediate their own intracellular translocation to the cytosol to deliver various therapeutic payloads.

“ETBs represent a new class of targeted biologics with predictable pharmacokinetics that have active intracellular properties that uniquely positions us to address delivery of RNAi molecules in a target directed manner.”

"We look forward to presenting these early preclinical data that demonstrates the unique and broad applications of our ETB platform technology," said Eric Poma, president and chief executive officer of Molecular Templates. "ETBs represent a new class of targeted biologics with predictable pharmacokinetics that have active intracellular properties that uniquely positions us to address delivery of RNAi molecules in a target directed manner."